Perimenopause First-Line Treatment Decision Framework

What Is Perimenopause and Why Does Timing Matter for Treatment?

Perimenopause is the multi-year transition leading up to menopause, defined as 12 consecutive months of amenorrhea. The Stages of Reproductive Aging Workshop (STRAW+10) criteria classify it as late reproductive stage through late menopausal transition, a span that averages 4 to 7 years but can extend to 10 [1]. Getting the timing right matters because treatment risks and options differ sharply between early perimenopause (irregular cycles, still ovulating) and late perimenopause (cycles >60 days apart, FSH consistently elevated).

STRAW+10 Staging in Clinical Practice

STRAW+10 uses cycle variability and FSH thresholds to stage the transition. In early perimenopause, cycle length varies by 7 or more days from the usual pattern. In late perimenopause, intervals exceed 60 days and serum FSH is typically above 25 IU/L on a cycle day-2 to day-5 draw, though values fluctuate enough that a single reading rarely confirms stage alone [1].

Clinically, knowing the stage shapes the hormonal choice. Early perimenopause with intact ovarian function and contraceptive need points toward a combined oral contraceptive. Late perimenopause without contraceptive need points toward low-dose menopausal hormone therapy. Neither is universally superior; the decision tree is symptom-driven and risk-stratified.

Why Symptom Burden Should Drive Urgency

Hot flashes and night sweats (collectively vasomotor symptoms, VMS) affect approximately 75% of perimenopausal women [2]. A 2015 analysis of the Study of Women's Health Across the Nation (SWAN) found that median VMS duration was 7.4 years, far longer than earlier estimates, with women who experienced symptoms earliest in the transition enduring the longest duration [3]. Sleep disruption, mood changes, and cognitive complaints cluster with VMS and substantially reduce quality of life. When symptoms are mild and infrequent, watchful waiting with lifestyle measures is reasonable. When they are moderate-to-severe, initiating treatment promptly prevents years of unnecessary suffering.

How to Choose Between a Low-Dose OCP and Menopausal HRT

The single most important branch point in the decision tree is whether the patient needs reliable contraception. Women in perimenopause remain at risk for pregnancy until 12 months after their final menstrual period; ovulation is erratic but still occurs [4].

When a Low-Dose Combined OCP Is the Right First Choice

A combined oral contraceptive containing 20 mcg ethinyl estradiol (or a progestogen-only pill for those with estrogen contraindications) accomplishes three things at once: contraception, cycle regulation, and VMS suppression. The 2022 ACOG Practice Bulletin 141 states that low-dose combined hormonal contraceptives "are an appropriate choice for perimenopausal women who are healthy, nonsmoking, and desire contraception" [4].

Standard perimenopausal OCP candidates share this profile:

• Age <50, still experiencing menstrual cycles, no contraindication to estrogen-containing contraception
• BMI <35 kg/m² (higher BMI raises VTE risk with ethinyl estradiol-containing pills)
• Nonsmoker or former smoker, because smoking after age 35 with a combined OCP raises stroke and MI risk enough to be a WHO Medical Eligibility Criteria Category 4 contraindication [5]
• Desire for cycle predictability

The 20 mcg ethinyl estradiol pill delivers roughly four to five times more estrogen exposure than a standard low-dose menopausal HRT regimen, so the risk-benefit calculation differs from postmenopausal hormone therapy.

When Low-Dose Menopausal HRT Fits Better

Once a woman no longer needs contraception and is in late perimenopause or early postmenopause, low-dose menopausal HRT becomes the preferred hormonal approach. The 2023 NAMS Position Statement concludes that for healthy women under 60 or within 10 years of menopause onset, "the benefits of hormone therapy outweigh the risks" for bothersome VMS [6].

Standard menopausal HRT regimens for the perimenopausal phase include:

• Transdermal estradiol 0.025 to 0.05 mg/day patch plus micronized progesterone 100 mg daily (for women with a uterus)
• Oral estradiol 0.5 to 1 mg daily plus a progestogen
• Low-dose vaginal estrogen alone when genitourinary symptoms dominate, without systemic progestogen needed

Transdermal estradiol is generally preferred over oral estradiol because first-pass hepatic metabolism is bypassed, producing lower triglycerides, lower C-reactive protein, and a more favorable VTE profile compared to oral preparations [7]. The ESTHER study (N=881) found that oral estrogen users had a four-fold increase in VTE risk versus non-users, while transdermal users showed no significant elevation [7].

Duration of Hormonal Therapy: What the Evidence Says

The Women's Health Initiative (WHI) enrolled postmenopausal women aged 50 to 79. Reanalysis of the younger subgroup (ages 50 to 59) showed that conjugated equine estrogen plus medroxyprogesterone acetate produced a hazard ratio of 1.26 for breast cancer after an average 5.6 years of use, but this was not statistically significant in that age band on its own [8]. The absolute risk increase was small: roughly 8 additional cases per 10,000 women-years. The NAMS 2023 statement notes that the risk associated with HRT use under 5 years in women under 60 is lower than the risk associated with obesity, sedentary lifestyle, or moderate alcohol intake [6].

Current guidance does not mandate an arbitrary 5-year cutoff. Shared decision-making governs duration. Annual reassessment of symptom burden and individual risk factors is the standard of care.

Non-Hormonal First-Line Options: When and How to Use Them

Non-hormonal therapies are first-line for women who have an absolute contraindication to hormones, who decline hormonal treatment after counseling, or who have a personal or strong family history of estrogen-sensitive malignancies.

Fezolinetant: The First FDA-Approved Non-Hormonal VMS Drug

Fezolinetant (Veozah, Astellas) is a selective neurokinin 3 (NK3) receptor antagonist that targets the hypothalamic KNDy neuron pathway responsible for thermoregulatory dysregulation in menopause. The FDA approved it in May 2023 based on the SKYLIGHT 1 and SKYLIGHT 2 trials.

SKYLIGHT 2 (N=501) showed that fezolinetant 45 mg daily reduced moderate-to-severe hot flash frequency by 63% from baseline at week 12, compared to 40% with placebo (P<0.001) [9]. Severity scores dropped by 2.5 points on a 4-point scale with the active drug versus 1.6 with placebo. The drug does not interact with estrogen receptors and carries no known VTE or breast cancer signal based on 12-month data.

One caution: fezolinetant is hepatically metabolized and the prescribing information requires liver function testing at baseline, 3 months, and 6 months [9]. It is contraindicated with strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin.

SSRIs, SNRIs, and Gabapentin

Before fezolinetant, paroxetine 7.5 mg (Brisdelle) held the only FDA approval for non-hormonal VMS treatment, based on a reduction of about 33% to 67% in hot flash frequency in two Phase 3 trials [10]. Other options with reasonable evidence include:

• Venlafaxine 37.5 to 75 mg daily: reduced VMS frequency by roughly 37 to 61% in randomized trials [10]
• Escitalopram 10 to 20 mg daily: MENQOL data showed a 47% VMS frequency reduction versus 29% for placebo [10]
• Gabapentin 300 mg three times daily: a Cochrane review of 8 trials found a mean reduction in hot flash composite score of 2.05 points versus placebo, though side effects including dizziness and somnolence limit tolerability for many patients [11]

No SSRI or SNRI is FDA-approved for VMS except paroxetine 7.5 mg. Off-label use is common and is explicitly acknowledged in both NAMS and ACOG guidance.

Lifestyle and Behavioral Measures as Adjuncts

No randomized controlled trial has demonstrated that lifestyle changes alone eliminate moderate-to-severe VMS, but several reduce frequency. A 2014 Cochrane review found that weight loss interventions in overweight women reduced hot flash scores by a clinically meaningful margin [11]. Paced breathing at 6 breaths per minute in two randomized crossover studies reduced hot flash frequency by about 50% during controlled sessions. These measures work best as adjuncts to medical therapy or for women with mild symptoms.

Addressing Genitourinary Syndrome of Menopause (GSM) as a Distinct Target

Genitourinary syndrome of menopause (GSM), encompassing vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs, affects an estimated 27 to 84% of postmenopausal women but is often underreported [12]. It is undertreated in perimenopause because it tends to emerge later than VMS yet worsens steadily without treatment.

Vaginal Estrogen: Low-Risk and Highly Effective

Low-dose vaginal estrogen (estradiol 10 mcg vaginal insert, Vagifem; or conjugated estrogen cream 0.5 g twice weekly) achieves local tissue restoration with minimal systemic absorption. Serum estradiol levels remain in the postmenopausal range with these doses. The NAMS 2013 position statement on vaginal atrophy, now updated under the GSM terminology, confirms that "low-dose vaginal estrogen is appropriate even for many breast cancer survivors" when symptoms are severe and non-hormonal options have failed, though oncology co-management is required [12].

Systemic progestogen is not needed when using vaginal estrogen at these low doses because endometrial absorption is negligible.

Non-Estrogen Vaginal Options

For patients who decline or cannot use vaginal estrogen:

• Ospemifene 60 mg oral daily (a selective estrogen receptor modulator): NEJM-published Phase 3 data showed statistically significant improvement in vaginal maturation index and dyspareunia at 12 weeks [13]
• Vaginal dehydroepiandrosterone (prasterone, Intrarosa) 6.5 mg nightly: FDA-approved in 2016, with Phase 3 data showing significant improvement in moderate-to-severe dyspareunia over 12 weeks [14]
• High-quality non-hormonal vaginal moisturizers (polycarbophil-based, applied 3 times weekly): provide symptomatic relief but do not restore vaginal epithelium

Risk Stratification Before Prescribing

Applying a structured risk-stratification step before initiating any therapy reduces harm and improves shared decision-making. The HealthRX Perimenopause Risk Ladder assigns patients to one of three tiers:

Tier 1: Standard hormonal candidates. No personal history of breast, endometrial, or ovarian cancer. No active VTE or known thrombophilia. Blood pressure below 140/90 mmHg. Nonsmoker or former smoker who quit more than 1 year ago. BMI <35 kg/m². These patients may receive a full hormonal menu: combined OCP (if contraception needed) or low-dose menopausal HRT.

Tier 2: Modified hormonal candidates. Controlled hypertension, migraine with aura (absolute contraindication to ethinyl estradiol-containing OCP but not to transdermal estradiol HRT), BMI 35 to 40 kg/m², or personal BRCA carrier without prior cancer. Transdermal estradiol HRT is generally preferred over oral or OCP. Oncology or hematology co-management may be warranted.

Tier 3: Non-hormonal candidates. Active or prior estrogen-sensitive malignancy, active VTE on anticoagulation, uncontrolled hypertension despite treatment, or patient preference to avoid hormones. Fezolinetant 45 mg daily is the preferred VMS therapy. Escitalopram or venlafaxine are alternatives. Vaginal prasterone or ospemifene for GSM.

Tier assignment is not permanent. A Tier 3 patient whose breast cancer oncologist approves low-dose vaginal estrogen after 3 years of remission may shift on that specific indication.

Monitoring Protocol After Treatment Initiation

Starting treatment is the easy part. Consistency in follow-up determines whether the chosen therapy is actually working and safe.

3-Month Check-In

At 3 months, evaluate:

1. VMS frequency and severity (a validated tool such as the Menopause Rating Scale or the Greene Climacteric Scale gives a reproducible score)
2. Adherence and tolerability
3. Blood pressure (all patients on estrogen-containing therapy)
4. Liver function tests (fezolinetant users only)
5. Any new contraindications that emerged

If VMS response is <50% reduction from baseline on a hormonal regimen, the dose may be titrated: transdermal estradiol 0.025 mg stepped to 0.05 mg, or oral estradiol 0.5 mg to 1 mg.

Annual Review

Every 12 months, the clinical picture should be reassessed with a full medical history update, breast exam, and determination of whether the patient has crossed into confirmed postmenopause (12 months of amenorrhea). Transition to a postmenopausal HRT protocol at that point is appropriate.

Bone density screening with DEXA is recommended by USPSTF at age 65 for average-risk women, but the Endocrine Society recommends earlier screening for women with premature or early menopause (<45 years) given accelerated bone loss in that population [15].

Special Populations: Surgical Menopause and Early Perimenopause Under 45

Women who undergo bilateral oophorectomy before age 45 experience abrupt surgical menopause rather than gradual perimenopause. The Endocrine Society's 2019 Clinical Practice Guideline on primary ovarian insufficiency strongly recommends hormone therapy "until at least age 50 to 51" in these patients to offset elevated risks of osteoporosis, cardiovascular disease, and cognitive decline that come with estrogen deprivation decades earlier than natural menopause [15].

The same logic applies to women with primary ovarian insufficiency (POI) diagnosed before age 40. The guideline notes that the WHI data, largely drawn from older postmenopausal women, "should not be extrapolated to women with POI or surgical menopause under 45" [15]. This is a clinically important distinction that is often missed in primary care.

Practical Prescribing: Starting Doses and Titration

| Indication | Agent | Starting Dose | Max Dose | Notes | |---|---|---|---|---| | VMS + contraception needed | Ethinyl estradiol / levonorgestrel 20 mcg / 100 mcg OCP | 1 tablet daily | As labeled | Avoid if smoker >35, migraine with aura, BMI >35 | | VMS, no contraception needed | Transdermal estradiol patch | 0.025 mg/day | 0.1 mg/day | Add micronized progesterone 100 mg daily if uterus intact | | VMS, hormone-free | Fezolinetant | 45 mg daily | 45 mg daily | Check LFTs at baseline, 3 mo, 6 mo | | VMS, hormone-free (alternative) | Venlafaxine | 37.5 mg daily x 1 week | 75 mg daily | Taper on discontinuation | | GSM only | Estradiol vaginal insert | 10 mcg nightly x 2 weeks | 10 mcg twice weekly | No systemic progestogen needed | | GSM, hormone-free | Prasterone vaginal insert | 6.5 mg nightly | 6.5 mg nightly | FDA-approved 2016 |

Doses shown are starting points. Individual titration based on response and tolerability is expected.